InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol in diseases with high unmet medical need. It is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. Its main pipeline products are INM-755 for epidermolysis bullosa (EB), a serious, debilitating orphan indication, and INM-088 for glaucoma.
Following the safety and tolerability data from the two Phase I trials in healthy volunteers, INM-755 is moving into a Phase II (755-201-EB) trial in up to 20 EB patients, with an anticipated treatment duration of 28 days. Regulatory applications are expected to be filed in several countries in Q2 CY21 with enrolment to begin in the second half of the calendar year. Also, the formulation for INM-088 has been finalized, with IND-enabling toxicology studies expected to begin in CY21 and filings for human clinical trials to begin in H1 CY22. Additionally, InMed recently announced a research collaboration involving its biosynthesis platform with BayMedica.
In this webinar, Eric Adams and Bruce Colwill will present an overview of the company’s recent operating and financial activities, followed by a brief Q&A session.